Skip to search formSkip to main contentSkip to account menu

Anti-CD20-engineered Toxin Body MT-3724

Known as: MT-3724 
An engineered toxin body (ETB) composed of the single-chain variable fragment (ScFv) from an antibody targeting CD20 that is linked to a modified… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
TPS8074Background: Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit… 
2019
2019
MT-3724 is a novel recombinant fusion protein consisting of a CD20 binding variable fragment (scFv) fused to Shiga-like toxin-I… 
Review
2019
Review
2019
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin Lymphoma (NHL… 
2019
2019
Introduction: Approximately 40% of all newly diagnosed Diffuse large B-cell lymphoma (DLBCL) patients are either refractory or… 
2018
2018
Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma (NHL) subtype with aggressive clinical demonstration characterized by the… 
2018
2018
7580Background: MT-3724 is a novel recombinant fusion protein consisting of a CD20 binding variable fragment (scFv) fused to… 
2017
2017
Mantle cell lymphoma (MCL) accounts for 6-8% of all non-Hodgkin lymphoma cases and is a therapeutic challenge. MCL is… 
2016
2016
Background Novel mechanisms of action (MOA) are needed for the treatment of NHL. Because of the ubiquity and persistence of CD20… 
2016
2016
Background Anti-CD20 monoclonal antibody (MAb) therapy is widely employed in the treatment of non-Hodgkin9s B-cell lymphoma (NHL… 
2014
2014
The B-cell membrane protein CD20 is expressed by both benign and neoplastic lymphocytes. It has been a superb target for…